|Bid||28.52 x 1000|
|Ask||28.65 x 3100|
|Day's Range||28.28 - 29.35|
|52 Week Range||23.83 - 45.02|
|Beta (3Y Monthly)||3.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 4, 2019 - Mar 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.29|
Biotech stocks like CRISPR Therapeutics (NASDAQ:CRSP) are inherently risky, and inherently volatile. CRISPR stock itself, only public for a little over two years, is a good example. CRSP stock went public at $14 — and cleared $70 this year.
The gene-editing pioneer reported third-quarter 2018 earnings and reported FDA acceptance of its first investigational new drug (IND) application.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors. Ms. Collins is a recognized leader in cell and gene therapy, molecular diagnostics, life sciences, and therapeutics. Prior to her most recent position as CEO of Human Longevity, Inc., she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of sickle cell disease and beta-thalassemia. In these experiments, the Company demonstrated HBG1/2 promoter-edited CD34+ cells robustly engrafted in mice without lineage skewing of red blood cell precursors. The Company reported these data today in an oral presentation at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego.
Crispr Therapeutics will launch a gene-editing therapy in the U.S. in 2022, an analyst predicted Friday as he initiated coverage with a buy rating.
The study, which Editas said will involve 10 to 20 patients, will be the second company-sponsored clinical trial in the U.S. of a drug based on CRISPR/Cas9 technology.
CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10). “The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine.
The researcher's claims, which have not yet been published in a scientific paper, prompted a swift outcry among Boston-area life sciences officials Monday, given that such genetic changes can be passed on to future generations.
Editas Medicine (EDIT) incurred general and administrative expenses of $13.33 million in the third quarter—compared to $12.63 million in the third quarter of 2017. The increase was due to higher stock-based compensation and employee-related expenses during this period.
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.
Editas Medicine (EDIT) is a leading genome editing company. The company’s product development strategy is to mainly target genetically defined diseases with a focus on debilitating illnesses.
CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
From filing its IND filing for EDIT-101 to new data on new engineered cell treatments, the genome editing company delivered just as promised in Q3.
Editas Medicine could be the next to test the widely watched gene editing technology CRISPR/Cas9 after filing a clinical trial application late last month, the company revealed Wednesday.
Editas (EDIT) delivered earnings and revenue surprises of 55.56% and 120.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 32 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual.
It was a busy month for gene editing stocks, which suffered from both CRISPR-specific news and the broader stock market's fall.